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Cerebral toxoplasmosis (Toxo) is rarely described in
children. The Romanian pediatric cohort consists of
children that have been infected parenterally in the late
’80s. We aimed to describe the prevalence, clinical find-
ings and outcome of Toxo in children and adolescents
from the Romanian Pediatric Cohort, that have been
diagnosed in the “Dr. Victor Babeş” Hospital, one of the
main reference centers for HIV from Romania
Cerebral toxoplasmosis was diagnosed based on CDC
case definition (presumptive and definitive diagnosis).
We reviewed retrospectively the charts of all 29 children
diagnosed with Toxo starting 1996, recording the demo-
graphic, HIV markers, antiretroviral treatment, clinical
and neuroimaging data, treatment and outcome of
Toxo.
The prevalence of Toxo was 4.8% from 604 patients
followed in the Hospital. Out of 29 patients diagnosed
with Toxo, 19 were girls and 28 had parenterally and 1
had vertically acquired HIV. The mean age at HIV
diagnosis was 11.5±6.5 years, and 15.6±5.3 years at
Toxo diagnosis. In 10 patients HIV was diagnosed con-
comitantly with Toxo. At onset 89.7% patients had focal
neurological signs and 62.1% had headache. Median
CD4 count was 60 (95% CI for median 27-95) lf/cmm.
28 patients had positive T. gondii IgG antibodies in
plasma and/or cerebrospinal fluid. Only 6 patients had
treatment with cotrimoxazole, most of them being trea-
ted with pyrimethamine/sulphadoxine combination and
alternatively with atovaquone. 69% of patients had any
adverse reactions to Toxo treatment. Most adverse reac-
tions were cutaneous in 10 patients (5 severe) and anemia
in 7 patients. Nine patients had antiretroviral therapy
(ART) before Toxo diagnosis, out of them 1 had mono, 1
dual therapy, 6 were failing cART and one patient had
immune reconstitution syndrome. Ten patients (34.5%)
died. The median survival time was 117 months. In uni-
variate analysis survival was correlated with shorter time
from onset to admission (p=0.04) while on multivariate
analysis diagnosis in the post-cART period was the only
factor associated with longer survival (p=0.03). 14 of 19
patients recovered with sequels, most of them motor
deficits.
Cerebral toxoplasmosis in this particular pediatric
cohort shared common features with that reported in
adults pertaining to prevalence in pre-cART period and
pathogenic mechanism. Survival was associated with a
more rapid diagnosis of cerebral toxoplasmosis and with
access to cART.
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